Posted by Michael Wonder on 29 Jun 2023
Secukinumab for the treatment of patients with moderate to severe hidradenitis suppurativa
29 June 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of secukinumab in the NHS in England.
Secukinumab is not recommended for the treatment of adults with active moderate to severe hidradenitis suppurativa (acne inversa) when the disease has not responded well enough to conventional systemic therapy.
